Cargando…

BBB opening with focused ultrasound in nonhuman primates and Parkinson’s disease patients: Targeted AAV vector delivery and PET imaging

Intracerebral vector delivery in nonhuman primates has been a major challenge. We report successful blood-brain barrier opening and focal delivery of adeno-associated virus serotype 9 vectors into brain regions involved in Parkinson’s disease using low-intensity focus ultrasound in adult macaque mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Blesa, Javier, Pineda-Pardo, José A., Inoue, Ken-ichi, Gasca-Salas, Carmen, Balzano, Tiziano, Del Rey, Natalia López-González, Reinares-Sebastián, Alejandro, Esteban-García, Noelia, Rodríguez-Rojas, Rafael, Márquez, Raquel, Ciorraga, María, del Álamo, Marta, García-Cañamaque, Lina, Ruiz de Aguiar, Santiago, Rachmilevitch, Itay, Trigo-Damas, Inés, Takada, Masahiko, Obeso, José A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115413/
https://www.ncbi.nlm.nih.gov/pubmed/37075119
http://dx.doi.org/10.1126/sciadv.adf4888
Descripción
Sumario:Intracerebral vector delivery in nonhuman primates has been a major challenge. We report successful blood-brain barrier opening and focal delivery of adeno-associated virus serotype 9 vectors into brain regions involved in Parkinson’s disease using low-intensity focus ultrasound in adult macaque monkeys. Openings were well tolerated with generally no associated abnormal magnetic resonance imaging signals. Neuronal green fluorescent protein expression was observed specifically in regions with confirmed blood-brain barrier opening. Similar blood-brain barrier openings were safely demonstrated in three patients with Parkinson’s disease. In these patients and in one monkey, blood-brain barrier opening was followed by (18)F-Choline uptake in the putamen and midbrain regions based on positron emission tomography. This indicates focal and cellular binding of molecules that otherwise would not enter the brain parenchyma. The less-invasive nature of this methodology could facilitate focal viral vector delivery for gene therapy and might allow early and repeated interventions to treat neurodegenerative disorders.